TLSA Tiziana Life Sciences PLC ADS

Tiziana Life Sciences Plc (the "Company") - Result of General Meeting

Tiziana Life Sciences Plc (the "Company") - Result of General Meeting
EN
02/10/2020

Underlying

TLSATiziana Life Sciences PLC ADS

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Tiziana Life Sciences PLC ADS

 PRESS RELEASE
Free
TLSA Tiziana Life Sc...

Tiziana Life Sciences to Present at BIO-Europe in Vienna, Highlighting...

Tiziana Life Sciences to Present at BIO-Europe in Vienna, Highlighting Innovative Immunomodulation Therapy BOSTON, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: ) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced its participation as a presenting company at BIO-Europe 2025. The event, Europe’s premier life sciences partnering conference, will take place November 3–5, 2025, at the Vienna Exhib...

October 29, 2025 1 EN
 PRESS RELEASE
Free
TLSA Tiziana Life Sc...

Tiziana Life Sciences Invited to Attend Life Sciences Innovation Forum...

Tiziana Life Sciences Invited to Attend Life Sciences Innovation Forum 2025 in Riyadh, Saudi Arabia BOSTON, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: ) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced that it has been invited to attend the J.P. Morgan Asset Management, Life Science Innovation Forum (LSIF) 2025 in Collaboration with KAIMRC, taking place October 1–2, 2025, at the King Sau...

September 30, 2025 1 EN
 PRESS RELEASE
Free
TLSA Tiziana Life Sc...

Tiziana to Advance TZLS-501 - Its Fully Human IL-6R Monoclonal Antibod...

Tiziana to Advance TZLS-501 - Its Fully Human IL-6R Monoclonal Antibody BOSTON, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: ) (“Tiziana” or the “Company”), today announces it will advance its second asset, a fully human anti-IL-6 receptor (“IL-6R”) monoclonal antibody, TZLS-501. There has been heightened industry activity in the IL-6 pathway space, underscored by Novartis’ recent acquisition of Tourmaline Bio for approximately $1.4 billion. Tiziana will pursue non-dilutive funding strategies for the development of TZLS-501 while continuing to advance intranasal...

September 25, 2025 1 EN
 PRESS RELEASE
Free
TLSA Tiziana Life Sc...

Tiziana Life Sciences Announces Poster Presentation on Intranasal Fora...

Tiziana Life Sciences Announces Poster Presentation on Intranasal Foralumab Clinical Trial at the 41st ECTRIMS Congress BOSTON, Sept. 24, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: ) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced that it will present a scientific poster at the 41st Congress of the European Committee for Treatment and Research of Multiple Sclerosis (ECTRIMS), being held September...

September 24, 2025 1 EN
 PRESS RELEASE
Free
TLSA Tiziana Life Sc...

Department of Defense Awards Grant to Advance Tiziana Life Sciences In...

Department of Defense Awards Grant to Advance Tiziana Life Sciences Intranasal Anti-CD3 Therapy for Spinal Cord Injury BOSTON, Sept. 15, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: ) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced that the U.S. Department of Defense (DoD) has awarded a research grant to study the use of intranasal anti-CD3 therapy in traumatic spinal cord injury (SCI). This fundin...

September 15, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch